Press Releases May 7, 2026 08:00 AM

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference Featuring CEO Krish S. Krishnan

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
KRYS

Krystal Biotech, a commercial-stage biotechnology company specializing in genetic medicines, announced its participation in the BofA Securities 2026 Health Care Conference. CEO Krish S. Krishnan will engage in a fireside chat and hold investor meetings, with a webcast available for public viewing. The company focuses on innovative gene therapy treatments, including its lead product VYJUVEK for dystrophic epidermolysis bullosa.

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
KRYS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Krystal Biotech will present at a major healthcare investor conference on May 13, 2026, offering exposure to institutional investors.
  • The company is commercial-stage, with a product approved in multiple major markets (USA, Europe, Japan) for a rare genetic condition.
  • Focus is on genetic medicines addressing diseases with high unmet medical needs, signaling ongoing pipeline development and innovation.

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.

A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 13, 2026 and will be posted on the Investors section of the Company’s website.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.

CONTACT
Investors and Media:                                                             
Stéphane Paquette, PhD
Krystal Biotech
[email protected]                                    


Risks

  • Market reception to investor presentations can be muted if no new data or strategic updates are provided, limiting stock price impact.
  • As a biotechnology firm, Krystal Biotech faces clinical development and regulatory approval risks for its investigational medicines, affecting future growth potential.
  • Commercial success depends on market adoption of VYJUVEK and progress of pipeline products, which can be uncertain due to competitive and reimbursement challenges.

More from Press Releases

OFA Group Completes Acquisition and Title Registration of Tokawa Coastal Property in Choshi, Japan Oct 9, 2026 Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical Oct 9, 2026 Fiverr to Release Third Quarter 2026 Results on October 29, 2026 Oct 9, 2026 Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences Oct 9, 2026 Rezolve Ai Opens Retail to Any AI Shopping Agent with RezolvePay, Targeting a Multi-Trillion-Dollar Commerce Opportunity Oct 9, 2026